Shruti Sharma, PhD
Vascular inflammation plays a critical role in the pathogenesis of diabetic retinopathy. Building on my experience in vascular biology and genomic medicine, my current research focuses on understanding the role of endothelial dysfunction on vascular attributes of diabetic retinopathy. The long-term goal of my lab is to study the role of interleukin-6 (IL-6) signaling in diabetic retinopathy and uncover precise molecular mechanisms to develop novel therapeutic targets. We are currently testing a pharmacological compound, sgp130Fc (fused chimera of extracellular gp130 and the Fc region of IgG1), to selectively inhibit the IL-6 trans-signaling pathway to prevent the inflammation and retinal vascular dysfunction associated with diabetic retinopathy. My lab utilizes both in-vitro and rodent models of diabetic retinopathy to conduct our research.
PhD, Biochemistry, University of Lucknow, Lucknow, India
I served as the Specialty Chief Editor of Frontiers in Oxidant Physiology (impact factor: 4.566) from 2012 to 2020 and led a team of 215 editors. The journal focuses on interdisciplinary research concerning genetic, biophysical, genomic, proteomic, cellular, molecular, biochemical, physiological, and pharmacological aspects of oxidants and redox active molecules, as well as the pathological events associated with oxidative stress.
Noninvasive technique collects sufficient tear fluid to look for biomarkers of health and disease
Jagwire | May 27, 2022
The protective outer layer of our eyes, called the tear film, contains thousands of proteins, which provide clues about wellness and disease, and scientists have fine-tuned what they say is a non-invasive and efficient way to look at those clues.
They anticipate that one day a tear fluid workup could be as routine as bloodwork
during a physical exam as well as in diagnosing a myriad of conditions from dry eye
disease to Alzheimer’s.
>> Read more